Humoral and Cellular Immune Responses of Solid Organ Transplant Patients on Belatacept to Three Doses of mRNA-Based Anti-SARS-CoV-2 Vaccine

Humoral and Cellular Immune Responses of Solid Organ Transplant Patients on Belatacept to Three Doses of mRNA-Based Anti-SARS-CoV-2 Vaccine

Background: Two doses of anti-SARS-CoV-2 mRNA-based vaccines are poorly immunogenic in solid organ transplant recipients (SOT). Methods: In total, 68 belatacept-treated SOT recipients followed at the Toulouse University Hospital were investigated. They were given three injections of the BNT162b2 mRN...

Full description

Bibliographic Details
Main Authors: Florence Abravanel, Olivier Marion, Arnaud Del Bello, Thomas Beunon, Raphaelle Romieu-Mourez, Chloé Couat, Mélanie Pucelle, Laetitia Staes, Joelle Guitard, Laure Esposito, Stanislas Faguer, Nassim Kamar, Jacques Izopet
Format: Article
Language:English
Published: MDPI AG 2022-02-01
Series:Vaccines
Subjects:
IgG SARS-CoV-2
anti-spike
solid organ transplant recipients
Online Access:https://www.mdpi.com/2076-393X/10/3/354

Internet

https://www.mdpi.com/2076-393X/10/3/354

Similar Items